Investing.com - Fulgent Genetics (NASDAQ: FLGT) reported fourth quarter EPS of $0.28, $0.57 better than the analyst estimate of $-0.29. Revenue for the quarter came in at $70.5M versus the consensus estimate of $66.32M.
Guidance
Fulgent Genetics sees FY 2024 EPS of $-1.05-$0.00 versus the analyst consensus of $-0.95.
Fulgent Genetics sees FY 2024 revenue of $280.00M versus the analyst consensus of $294.20M.
Fulgent Genetics's stock price closed at $25.48. It is down -7.24% in the last 3 months and down -20.00% in the last 12 months.
Fulgent Genetics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Fulgent Genetics's stock price’s past reactions to earnings here.
According to InvestingPro, Fulgent Genetics's Financial Health score is "good performance".
Check out Fulgent Genetics's recent earnings performance, and Fulgent Genetics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar